Security
BioAtla, Inc. Common Stock · BCAB
BCABOTCCommon stockCurrentCIK 1826892Updated Nov 2, 2026
BCAB price & chart
Loading TradingView…
OTC:BCAB on TradingView ↗About the company
We are a clinical-stage biopharmaceutical company developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Our CABs capitalize on our proprietary discoveries with respect to tumor biology, enabling us to target known, validated tumor antigens that have previously been difficult or impossible to target. Our novel CAB therapeutic candidates exploit characteristic pH differences between the tumor microenvironment and healthy tissue. Unlike healthy tissue, the tumor microenvironment is acidic, and we have designed our antibodies to selectively bind to their targets on tumor cells under acidic pH conditions but not on targets in normal tissues. Our proprietary approach is to identify the necessary targeting and potency required for cancer cell destruction, while aiming to eliminate or greatly reduce on-target, off-tumor toxicity—one of the fundamental challenges of existing cancer therapies.
In the news
No coverage from other publishers is available.
Recent filings
EFFECT filing
424B3 filing
RW filing
S-1 filing
Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement · Unregistered Sales of Equity Securities
Items 1.01, 1.02, 3.02, 9.01
Show 5 more recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
4 filing
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01
10-Q filing
Submission of Matters to a Vote of Security Holders
Items 5.07
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 15,908,000Source | 62,236,000Source | 9,506,000Source | 27,129,000Source | 68,638,000Source | 8,566,000Source | 38,290,000Source | 89,197,000Source | 13,828,000Source | 52,422,000Source | 119,658,000Source | 225,736,000Source |
| Property, Plant and Equipment, NetUSD | 324,000Source | 906,000Source | 0Source | 380,000Source | 1,134,000Source | 0Source | 495,000Source | 1,363,000Source | 120,000Source | 678,000Source | 1,603,000Source | 2,728,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 8,320,000Source | 56,516,000Source | 1,544,000Source | 18,207,000Source | 61,662,000Source | 1,961,000Source | 32,363,000Source | 80,630,000Source | 7,118,000Source | 49,046,000Source | 111,471,000Source | 215,507,000Source |
| Assets, CurrentUSD | 9,670,000Source | 60,567,000Source | 4,258,000Source | 20,613,000Source | 66,493,000Source | 3,093,000Source | 37,537,000Source | 86,425,000Source | 8,013,000Source | 51,232,000Source | 116,406,000Source | 220,431,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,350,000Source | 4,051,000Source | 714,000Source | 2,406,000Source | 4,831,000Source | 1,132,000Source | 5,174,000Source | 5,795,000Source | 895,000Source | 2,186,000Source | 4,935,000Source | 4,924,000Source |
| Operating Lease, Right-of-Use AssetUSD | 5,751,000Source | 763,000Source | 5,085,000Source | 6,000,000Source | 1,011,000Source | 5,310,000Source | 258,000Source | 1,255,000Source | 5,532,000Source | 512,000Source | 1,495,000Source | 2,423,000Source |
| Other Assets, NoncurrentUSD | 163,000Source | 0Source | 163,000Source | 163,000Source | 0Source | 163,000Source | — | 154,000Source | 163,000Source | 0Source | 154,000Source | 154,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 47,145,000Source | 39,268,000Source | 45,742,000Source | 43,874,000Source | 37,268,000Source | 45,875,000Source | 37,743,000Source | 39,481,000Source | 50,017,000Source | 38,157,000Source | 48,986,000Source | 45,397,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — |
| Common Stock, Value, IssuedUSD | 6,000Source | 5,000Source | 0Source | 6,000Source | 5,000Source | 0Source | 6,000Source | 5,000Source | 6,000Source | 6,000Source | 5,000Source | 5,000Source |
| Additional Paid in CapitalUSD | 504,619,000Source | 494,118,000Source | 515,302,000Source | 503,333,000Source | 491,934,000Source | 514,681,000Source | 501,914,000Source | 489,208,000Source | 509,451,000Source | 500,298,000Source | 486,930,000Source | 473,135,000Source |
| Retained Earnings (Accumulated Deficit)USD | -535,862,000Source | -471,155,000Source | -551,538,000Source | -520,084,000Source | -460,569,000Source | -551,990,000Source | -501,373,000Source | -439,497,000Source | -545,646,000Source | -486,039,000Source | -416,263,000Source | -292,801,000Source |
| Stockholders' Equity Attributable to ParentUSD | -31,237,000Source | 22,968,000Source | -36,236,000Source | -16,745,000Source | 31,370,000Source | -37,309,000Source | 547,000Source | 49,716,000Source | -36,189,000Source | 14,265,000Source | 70,672,000Source | 180,339,000Source |
| Liabilities and EquityUSD | 15,908,000Source | 62,236,000Source | 9,506,000Source | 27,129,000Source | 68,638,000Source | 8,566,000Source | 38,290,000Source | 89,197,000Source | 13,828,000Source | 52,422,000Source | 119,658,000Source | 225,736,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 17,984,000Source | 19,462,000Source | 21,021,000Source | 16,600,000Source | 17,462,000Source | 20,692,000Source | 16,006,000Source | 19,260,000Source | 21,922,000Source | 14,540,000Source | 28,344,000Source | 23,131,000Source |
| Operating Lease, Liability, CurrentUSD | 1,173,000Source | 1,251,000Source | 1,570,000Source | 805,000Source | 1,662,000Source | 1,559,000Source | 554,000Source | 1,509,000Source | 1,427,000Source | 836,000Source | 1,624,000Source | 1,521,000Source |
| Accounts Payable, CurrentUSD | 5,851,000Source | 2,928,000Source | 12,705,000Source | 4,643,000Source | 1,356,000Source | 12,123,000Source | 4,698,000Source | 3,446,000Source | 8,194,000Source | 1,902,000Source | 3,819,000Source | 4,231,000Source |
| Operating Lease, Liability, NoncurrentUSD | 5,008,000Source | 0Source | 4,293,000Source | 5,240,000Source | 0Source | 4,535,000Source | — | 415,000Source | 4,773,000Source | 0Source | 836,000Source | 2,460,000Source |
| Additional Financial Items | ||||||||||||
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 1,162,000Source | 183,000Source | 545,000Source | 935,000Source |
| Accounts Receivable, after Allowance for Credit Loss, Current | — | — | —Source | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 120,000Source | 183,000Source | 373,000Source | 925,000Source | 1,221,000Source | 1,199,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 1,292,000Source | 2,194,000Source | 619,000Source | 1,377,000Source | 956,000Source | 1,645,000Source | 5,434,000Source | 8,921,000Source | 13,544,000Source | 14,563,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -5,267,000Source | -16,288,000Source | -48,204,000Source | -71,936,000Source | -104,015,000Source | -90,420,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | 0Source | — | 0Source | -98,000Source | -265,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 110,000Source | -395,000Source | 6,276,000Source | 9,511,000Source | 77,000Source | 61,213,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 8,320,000Source | 56,516,000Source | 1,544,000Source | 18,207,000Source | 1,961,000Source | 32,363,000Source | 7,118,000Source | 49,046,000Source | 111,471,000Source | 215,507,000Source |
| Additional Financial Items | ||||||||||||
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | -185,000Source | 0Source | -2,000Source | -13,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| General and Administrative ExpenseUSD | — | — | 4,250,000Source | 5,875,000Source | 2,931,000Source | 4,963,000Source | 4,726,000Source | 5,259,000Source | 17,732,000Source | 21,848,000Source | 25,956,000Source | 28,793,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Investment Income, InterestUSD | — | — | 133,000Source | 692,000Source | 16,000Source | 233,000Source | 37,000Source | 400,000Source | 843,000Source | 3,369,000Source | 6,312,000Source | 1,648,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -15,778,000Source | -10,586,000Source | 452,000Source | -18,711,000Source | -6,344,000Source | -15,334,000Source | -59,607,000Source | -69,776,000Source | -123,462,000Source | -106,482,000Source |
| Operating ExpensesUSD | — | — | 13,789,000Source | 22,270,000Source | 6,273,000Source | 18,647,000Source | 9,308,000Source | 17,614,000Source | 61,305,000Source | 84,943,000Source | 129,687,000Source | 108,140,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -1,989,000Source | 684,000Source | 225,000Source | -64,000Source | 2,964,000Source | 2,280,000Source | -302,000Source | 4,167,000Source | 6,225,000Source | 1,658,000Source |
| Payments of Financing CostsUSD | — | — | — | — | — | — | 289,000Source | 366,000Source | 897,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 0Source | 9,215,000Source | 0Source | 61,682,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Restructuring CostsUSD | — | — | 0Source | — | 0Source | 0Source | 500,000Source | 600,000Source | 600,000Source | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -13,789,000Source | -11,270,000Source | 227,000Source | -18,647,000Source | -9,308,000Source | -17,614,000Source | -59,305,000Source | -73,943,000Source | -129,687,000Source | -108,140,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -1,989,000Source | 684,000Source | 225,000Source | -64,000Source | 2,964,000Source | 2,280,000Source | -302,000Source | 4,167,000Source | 6,225,000Source | 1,658,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -15,778,000Source | -10,586,000Source | 452,000Source | -18,711,000Source | -6,344,000Source | -15,334,000Source | -59,607,000Source | -69,776,000Source | -123,462,000Source | -106,482,000Source |
| Earnings Per Share, BasicUSD per share | — | — | — | — | 0.27Source | -15.99Source | -4.22Source | -13.16Source | -1.01Source | -1.44Source | -2.58Source | -2.74Source |
| Earnings Per Share, DilutedUSD per share | — | — | — | — | 0.27Source | -15.99Source | -4.22Source | -13.16Source | -1.01Source | -1.44Source | -2.58Source | -2.74Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | — | — | 1,660,586Source | 1,170,087Source | 1,501,649Source | 1,164,984Source | 58,827,934Source | 48,573,364Source | 47,777,568Source | 38,927,268Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | — | 1,661,709Source | 1,170,087Source | 1,501,649Source | 1,164,984Source | 58,827,934Source | 48,573,364Source | 47,777,568Source | 38,927,268Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 4,250,000Source | 5,875,000Source | 2,931,000Source | 4,963,000Source | 4,726,000Source | 5,259,000Source | 17,732,000Source | 21,848,000Source | 25,956,000Source | 28,793,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Investment Income, InterestUSD | — | — | 133,000Source | 692,000Source | 16,000Source | 233,000Source | 37,000Source | 400,000Source | 843,000Source | 3,369,000Source | 6,312,000Source | 1,648,000Source |
| Operating ExpensesUSD | — | — | 13,789,000Source | 22,270,000Source | 6,273,000Source | 18,647,000Source | 9,308,000Source | 17,614,000Source | 61,305,000Source | 84,943,000Source | 129,687,000Source | 108,140,000Source |
| Research and Development ExpenseUSD | — | — | 9,539,000Source | 16,395,000Source | 3,342,000Source | 13,684,000Source | 4,582,000Source | 12,355,000Source | 43,573,000Source | 63,095,000Source | 103,731,000Source | 79,347,000Source |
| Restructuring CostsUSD | — | — | 0Source | — | 0Source | 0Source | 500,000Source | 600,000Source | 600,000Source | — | — | — |
| Other Expenses | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
Offerings
Registration 333-299532
Registration 333-292784
Filing attachments
n5620x9_ex107.htm · S-1 · 2026-10-20
Exhibit 107 Calculation of Filing Fee Tables - Form S-1 (Form Type)N/A BioAtla, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Security Fee Amount Proposed Maximum Fee Amount Carry Carry Carry Filing …
Read attachment ↗n5620x9_ex4-4.htm · S-1 · 2026-10-20
Exhibit 4.4 [FORM OF COMMITMENT FEE WARRANT] THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND NEITHER THE SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT OR SUCH LAWS OR AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT AND SUCH LAWS WHICH, IN THE OPINION OF COUNSEL, IS AV…
Read attachment ↗bcab-ex4_1.htm · 8-K · 2026-10-20
Exhibit 4.1 [FORM OF COMMITMENT FEE WARRANT] THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND NEITHER THE SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT OR SUCH LAWS OR AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT AND SUCH LAWS WHICH, IN THE OPINION OF COUNSEL, IS AV…
Read attachment ↗bcab-ex99_1.htm · 8-K · 2026-04-02
EX-99.1 2 bcab-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CERTIFICATE OF MERGER MERGING BA MERGER SUB, INC. WITH AND INTO BIOATLA, INC. (Pursuant to Section 251 of the Delaware General Corporation Law) BioAtla, Inc., a corporation organized and existing under the Delaware General Corporation Law, does hereby certify: FIRST: The name and state of incorporation of each of the constituent corporations in the merger are: (i) BA Merger Sub, Inc., which is incorporated under the laws of the…
Read attachment ↗bcab-ex99_1.htm · 8-K · 2026-03-31
EX-99.1 2 bcab-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and business Highlights - Initiated a formal process to monetize assets - Implemented a restructuring plan to significantly reduce operating expenses and extend runway SAN DIEGO, March 31, 2026 - BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the…
Read attachment ↗bcab-ex99_2.htm · 8-K · 2026-03-31
EX-99.2 3 bcab-ex99_2.htm EX-99.2 Corporate Presentation March 2026 Conditionally Active Biologics: Transforming Cancer Therapy Important Notices & Disclaimers This presentation (the “Presentation”) by BioAtla, Inc. (“we”, “us”, “our”, “BioAtla”, or the “Company”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to statements we make regard…
Read attachment ↗